Search results
Results from the WOW.Com Content Network
Trigeminal neuralgia (TN or TGN), also called Fothergill disease, tic douloureux, trifacial neuralgia, or suicide disease, is a long-term pain disorder that affects the trigeminal nerve, [7] [1] the nerve responsible for sensation in the face and motor functions such as biting and chewing.
The trigeminal nerve.. ATN is usually attributed to inflammation or demyelination, with increased sensitivity of the trigeminal nerve.These effects are believed to be caused by infection, demyelinating diseases, or compression of the trigeminal nerve (by an impinging vein or artery, a tumor, dental trauma, accidents, or arteriovenous malformation) and are often confused with dental problems.
Download as PDF; Printable version; In other projects Wikidata item; ... Trigeminal neuralgia This page was last edited on 8 September 2014, at 06:04 (UTC). ...
Microvascular decompression (MVD), also known as the Jannetta procedure, [1] is a neurosurgical procedure used to treat trigeminal neuralgia (along with other cranial nerve neuralgias), a pain syndrome characterized by severe episodes of intense facial pain, and hemifacial spasm.
Jackie Galgey, 45, shares in a personal essay her experience with trigeminal neuralgia, also called the suicide disease, which caused her one-sided facial pain.
Trigeminal trophic syndrome is a rare disease caused by the interruption of peripheral or central sensory pathways of the trigeminal nerve. A slowly enlarging, uninflamed ulcer can occur in the area that has had trigeminal nerve damage; including but not limited to the cheek beside the ala nasi .
Cluster headache is a neurological disorder characterized by recurrent severe headaches on one side of the head, typically around the eye(s). [1] There is often accompanying eye watering, nasal congestion, or swelling around the eye on the affected side. [1]
Trigeminal nerve stimulation (TNS) or external Trigeminal nerve stimulation (eTNS) is a non-invasive, non-medication therapy for Attention deficit hyperactivity disorder approved in the United States by the FDA for the treatment of ADHD in children ages 7–12. [1] [2] [3] It is also used off-label to treat ADHD in adults. [4]